Modified release preparations containing oxcarbazepine and derivatives thereof
Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
1. A pharmaceutical controlled release formulation comprising a homogeneous matrix, which comprises (a) oxcarbazepine, (b) a matrix-forming polymer selected from the group consisting of cellulosic polymers, alginates, gums, cross-linked polyacrylic acid, carageenan, polyvinyl pyrrolidone, polyethylene oxides, and polyvinyl alcohol, and (c) at least one agent that enhances the solubility of oxcarbazepine.
2. The formulation of claim 1 , wherein the at least one agent that enhances the solubility of oxcarbazepine is selected from the group consisting of surface active agents, complexing agents, cyclodextrins, and pH modifying agents.
3. The formulation of claim 2 , wherein the surface active agent is selected from the group consisting of sodium docusate, sodium lauryl sulfate, sodium stearyl fumarate, polyethylene oxide (PEO) modified sorbitan monoesters, fatty acid sorbitan esters, polyethylene oxide-polypropylene oxide-(poly(ethylene oxide)) block copolymers, or combinations thereof.
4. The formulation of claim 1 , wherein in vitro:
(i) between 20 and 74% of the total oxcarbazepine is released by 2 hours; and
(ii) between 44 and 96% of the total oxcarbazepine is released by 4 hours.
5. The formulation of claim 1 , wherein the cellulosic polymers are selected from the group consisting of hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), methylcellulose (MC), powdered cellulose, cellulose acetate, sodium carboxymethylcellulose, calcium salt of carboxymethylcellulose, and ethylcellulose.
6. The formulation of claim 1 , wherein the matrix-forming polymer is present in the amount of from 1% to 50% by weight of the formulation.
7. The formulation of claim 1 , further comprising at least one release promoting agent.
8. The formulation of claim 7 , wherein the at least one release promoting agent comprises a polymer having pH dependent solubility that dissolves at pH values of more than 5.
9. The formulation of claim 8 , wherein the polymer having pH dependent solubility dissolves at pH values of more than 6.
10. The formulation of claim 7 , wherein the release promoting agent is incorporated in an amount from 10% to 90% by weight of the formulation, and the agent that enhances the solubility of oxcarbazepine is incorporated in an amount from 1% to 80% by weight of the formulation.
11. The formulation of claim 10 , wherein the release promoting agent is incorporated in an amount from 30% to 70% by weight of the formulation, and the agent that enhances the solubility of oxcarbazepine is incorporated in an amount from 1% to 80% by weight of the formulation.
12. The formulation of claim 1 , further comprising a lubricant selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, stearic acid, polyethylene glycol, leucine, glyceryl behenate, sodium stearyl fumarate, hydrogenated vegetable oil, and wax.
13. The formulation of claim 12 , wherein the wax is selected from the group consisting of beeswax, carnauba wax, cetyl alcohol, glyceryl stearate, glyceryl palmitate, and stearyl alcohol.
14. The formulation of claim 12 , wherein the lubricant is incorporated in an amount of from 0.1% to 20% by weight of the formulation.
15. The formulation of claim 1 , wherein the amount of oxcarbazepine is effective to produce a steady state blood level of monohydroxy derivative of oxcarbazepine in the range of about 2 μg/ml to about 10 μg/ml.
16. The formulation of claim 1 , wherein the amount of oxcarbazepine is 600 mg.
17. The formulation of claim 1 , in the form of pellets, tablets, granules or capsules.
18. The formulation of claim 17 , in the form of tablets.
19. The formulation of claim 18 , wherein the tablets comprise 600 mg of oxcarbazepine.
20. The formulation of claim 7 , wherein the at least one release promoting agent comprises a polymer having pH dependent solubility that dissolves at pH values of more than 4.